![Benjamin Hohl](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Fortuna: 2 M $ al 31/05/2026
Benjamin Hohl is currently CFO & Head-Corporate Development at Enliven Therapeutics, Inc., a position held since 2023.
Mr. Hohl completed undergraduate education at the University of California, Los Angeles.
| Empresa | Fecha | Número de acciones | Valoración | Fecha de valoración |
|---|---|---|---|---|
| 17/06/2026 | 51.000 ( 0,08 % ) | 2 M $ | 31/05/2026 |
| Empresas | Cargo | Inicio |
|---|---|---|
| ENLIVEN THERAPEUTICS, INC. | Director Financiero/CFO | 23/02/2023 |
Activas
Inactivas
Empresas cotizadas
Empresas privadas
| Empresas privadas | 2 |
|---|---|
University of California, Los Angeles
 University of California, Los Angeles Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Enliven Therapeutics, Inc.
 Enliven Therapeutics, Inc. BiotechnologyHealth Technology Operates as a clinical stage precision oncology company that develops molecule therapies | Health Technology |
Selecciona tu edición
Toda la información financiera adaptada al ámbito nacional.
